•
IP
IPHA
Innate Pharma S.A. ADS
yahoo--
Price Chart
Market Cap
163.05M
Volume
6.27K
52W High
$2.63
52W Low
$1.63
Open
$0.00
Prev Close
$1.81
Day Range
0.00 - 0.00
About Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Latest News
Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer
GlobeNewswire Inc.•Nov 6
Non-Hodgkin’s Lymphoma Market Forecast to Surge with Growing Adoption of Targeted and Cell-Based Therapies | DelveInsight
GlobeNewswire Inc.•Jul 24
Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsight
GlobeNewswire Inc.•Jul 21
All You Need to Know About Innate Pharma (IPHA) Rating Upgrade to Buy
Zacks Investment Research•Apr 10
Innate Pharma (IPHA) Gains as FDA Lifts Hold on Lymphoma Study
Zacks Investment Research•Jan 4
Innate (IPHA) Gains as Blood Cancer Drug Gets Fast Track Tag
Zacks Investment Research•Jun 9
Why Shares of Innate Pharma Jumped Thursday
The Motley Fool•Jun 8
Why Shares of Chinese Companies Are Trading Higher? Here Are 55 Stocks Moving In Tuesday's Mid-Day Session
Benzinga•Dec 27